Adial Pharmaceuticals, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-13. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Reported
As of August 10, 2026, Adial Pharmaceuticals, Inc. (the "Company") anticipates that the employment of its current President and Chief Executive Officer, Cary Claiborne, will be terminated effective promptly after the Company's 2026 Annual Meeting of Stockholders ("the 2026 Annual Meeting") if certain of the proposals being presented to stockholders are approved (the "Stockholder Approval"), and that Matthew Davidson, the Company's Chief Development Officer and a member of our Board of Directors, will be appointed as the Company's President and Chief Executive Office.
Departing: Tony Goodman
Effective Time, Tony Goodman resigned as a Class I Director of the Company.
Appointed: Matt Davidson, Chief Development Officer
Mr. Goodman did not resign as a result of any disagreements with the Board or the Company. 6 Appointment of Directors and Chief Development Officer On June 11, 2026, in connection with the Merger, effective immediately after the First Effective Time, Matt Davidson, Ph.D., was appointed to the Board as a Class I Director, to fill the vacancy created by the resignation of Mr. Goodman, with a term expiring at the Company's 2028 Annual Meeting of Stockholders, and Wendy B. Young, Ph.
Find people with the same kind of experience as the Chief Development Officer at Adial Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Development Officer at Adial Pharmaceuticals, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Adial Pharmaceuticals, Inc. is in the news or changes leadership.
Get an alert when Adial Pharmaceuticals, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Adial Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.